Stefana S. Impera
Catania, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate-1-Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI).
Journal: Hematological oncology
Published: November 13, 2025
The influence of patient engagement and self-efficacy on self-care in myeloproliferative neoplasms: A mediation analysis.
Journal: European journal of oncology nursing : the official journal of European Oncology Nursing Society
Published: October 29, 2025
Real-World Efficacy Profile of Compassionate Use of Asciminib in an Italian, Multi-Resistant Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Patient Population.
Journal: Hematological oncology
Published: February 14, 2025
Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real-world setting: Interim results of the Italian observational study (ROMEI).
Journal: Cancer
Published: October 24, 2024
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the "RAMP" Italian multicenter prospective study.
Journal: Annals of hematology
Published: November 27, 2023
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 09, 2023
Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI).
Journal: Leukemia & lymphoma
Published: September 15, 2021
BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors.
Journal: Frontiers in oncology
Published: April 03, 2019
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib.
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib.
Journal: International journal of molecular sciences
Published: March 23, 2019
"On-demand" treatment with Thrombopoietin mimetics as "bridge to recovery" from chemotherapy in chronic immune thrombocytopenia patients with cancer. A single centre experience in nine patients.
Journal: British journal of haematology
Published: May 04, 2017
High BCR-ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 01, 2017
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
Journal: The Lancet. Haematology
Published: October 31, 2016
Last Updated: 09/26/2026